当前位置: X-MOL 学术Cytom. Part B Clin. Cytom. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Utility of CD36 as a novel addition to the immunophenotypic signature of RAM‐phenotype acute myeloid leukemia and study of its clinicopathological characteristics
Cytometry Part B: Clinical Cytometry ( IF 3.4 ) Pub Date : 2020-08-31 , DOI: 10.1002/cyto.b.21943
Devasis Panda 1 , Gaurav Chatterjee 1 , Rohan Sardana 1 , Twinkle Khanka 1 , Sitaram Ghogale 1 , Nilesh Deshpande 1 , Yajamanam Badrinath 1 , Dhanalaxmi Shetty 2 , Gaurav Narula 3 , Shripad Banavali 3 , Nikhil V Patkar 1 , Sumeet Gujral 1 , Papagudi G Subramanian 1 , Prashant R Tembhare 1
Affiliation  

In 2016, Children Oncology Group (COG) described a new high‐risk subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic‐signature, RAM‐phenotype (RAM‐AML). Data on clinical and laboratory features of RAM‐AML are still limited to COG report only. Herein, we report the clinicopathological characteristics and detailed immunophenotypic features of RAM‐AML patients. In COG report, 38% of RAM‐AML belonged to acute megakaryoblastic leukemia (AMKL)‐subtype. Hence, we further compared the immunophenotypic features RAM‐AML with non‐RAM‐AMKL diagnosed during the same study period.

中文翻译:

CD36 作为 RAM 表型急性髓系白血病免疫表型特征的新补充及其临床病理学特征的研究

2016 年,儿童肿瘤学小组 (COG) 描述了一种新的高危急性髓系白血病 (AML) 亚型,具有独特的免疫表型特征 RAM 表型 (RAM-AML)。RAM-AML 的临床和实验室特征数据仍仅限于 COG 报告。在此,我们报告了 RAM-AML 患者的临床病理特征和详细的免疫表型特征。在 COG 报告中,38% 的 RAM-AML 属于急性巨核细胞白血病 (AMKL) 亚型。因此,我们进一步比较了同一研究期间诊断出的 RAM-AML 和非 RAM-AMKL 的免疫表型特征。
更新日期:2020-08-31
down
wechat
bug